TY - JOUR
T1 - Alcohol Consumption and Cardiovascular Health
AU - Krittanawong, Chayakrit
AU - Isath, Ameesh
AU - Rosenson, Robert S.
AU - Khawaja, Muzamil
AU - Wang, Zhen
AU - Fogg, Sonya E.
AU - Virani, Salim S.
AU - Qi, Lu
AU - Cao, Yin
AU - Long, Michelle T.
AU - Tangney, Christy C.
AU - Lavie, Carl J.
N1 - Funding Information:
The authors would like to thank Dr. JoAnn E. Manson, MD, DrPH, MACP (Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Mass), Dr. Kenneth J. Mukamal, MD (Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard TH Chan School of Public Health, Boston, Mass), and Dr. Meir Stampfer, MD, DrPH (Harvard T.H. Chan School of Public Health) for their suggestions and comments on this article. Funding: None. Conflicts of Interest: Dr. Krittanawong discloses the following relationships – Member of the American College of Cardiology Solution Set Oversight Committee, the American Heart Association Committee of the Council on Genomic and Precision Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial board), JACC: Asia (Section Editor), The Journal of Scientific Innovation in Medicine (Associate Editor), and Frontiers in Cardiovascular Medicine (Associate Editor). Dr. Rosenson receives research funding to his institution from Amgen, Arrowhead, Lilly, NIH, Novartis, Regeneron; consulting fees from Amgen, Lilly, Novartis, Regeneron, non-promotional speaking fees from Amgen, Kowa; royalties from Wolters Kluwer for UpToDate, and has stock holdings in MediMergent LLC. Dr. Virani discloses the following Grant support: Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family. Honorarium: American College of Cardiology (Associate Editor for Innovations, ACC.org). Steering Committee: Patient and Provider Assessment of Lipid Management (PALM) registry at Duke Clinical Research Institute (no financial remuneration). Dr. Qi is supported by grants from the National Heart, Lung, and Blood Institute (HL071981, HL034594, HL126024), the National Institute of Diabetes and Digestive and Kidney Diseases (DK115679, DK091718, DK100383, DK078616), the Fogarty International Center (TW010790), Tulane Research Centers of Excellence Awards. Dr. Qi is also supported by P30DK072476 and NIGMS P20GM109036. Dr. Long is supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases K23 DK113252, the Doris Duke Charitable Foundation Grant #2019085, Gilead Sciences Research Scholars Award, Echosens Corporation, the Boston University. Dr. Tangney is an UpTodate consultant. Other authors have no disclosure.
Funding Information:
Conflicts of Interest: Dr. Krittanawong discloses the following relationships – Member of the American College of Cardiology Solution Set Oversight Committee, the American Heart Association Committee of the Council on Genomic and Precision Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial board), JACC: Asia (Section Editor), The Journal of Scientific Innovation in Medicine (Associate Editor), and Frontiers in Cardiovascular Medicine (Associate Editor). Dr. Rosenson receives research funding to his institution from Amgen, Arrowhead, Lilly, NIH, Novartis, Regeneron; consulting fees from Amgen, Lilly, Novartis, Regeneron, non-promotional speaking fees from Amgen, Kowa; royalties from Wolters Kluwer for UpToDate, and has stock holdings in MediMergent LLC. Dr. Virani discloses the following Grant support: Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family. Honorarium: American College of Cardiology (Associate Editor for Innovations, ACC.org). Steering Committee: Patient and Provider Assessment of Lipid Management (PALM) registry at Duke Clinical Research Institute (no financial remuneration). Dr. Qi is supported by grants from the National Heart, Lung, and Blood Institute (HL071981, HL034594, HL126024), the National Institute of Diabetes and Digestive and Kidney Diseases (DK115679, DK091718, DK100383, DK078616), the Fogarty International Center (TW010790), Tulane Research Centers of Excellence Awards. Dr. Qi is also supported by P30DK072476 and NIGMS P20GM109036. Dr. Long is supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases K23 DK113252, the Doris Duke Charitable Foundation Grant #2019085, Gilead Sciences Research Scholars Award, Echosens Corporation, the Boston University. Dr. Tangney is an UpTodate consultant. Other authors have no disclosure.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022
Y1 - 2022
N2 - Background: Studies evaluating alcohol consumption and cardiovascular diseases have shown inconsistent results. Methods: We performed a systematic review of peer-reviewed publications from an extensive query of Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception to March 2022 for all studies that reported the association between alcohol consumption in terms of quantity (daily or weekly amounts) and type of beverage (wine, beer or spirit) and cardiovascular disease events. Results: The study population included a total of 1,579,435 individuals based on 56 cohorts from several countries. We found that moderate wine consumption defined as 1-4 drinks per week was associated with a reduction in risk for cardiovascular mortality when compared with beer or spirits. However, higher risk for cardiovascular disease mortality was typically seen with heavier daily or weekly alcohol consumption across all types of beverages. Conclusions: It is possible that the observational studies may overestimate the benefits of alcohol for cardiovascular disease outcomes. Although moderate wine consumption is probably associated with low cardiovascular disease events, there are many confounding factors, in particular, lifestyle, genetic, and socioeconomic associations with wine drinking, which likely explain much of the association with wine and reduced cardiovascular disease events. Further prospective study of alcohol and all-cause mortality, including cancer, is needed.
AB - Background: Studies evaluating alcohol consumption and cardiovascular diseases have shown inconsistent results. Methods: We performed a systematic review of peer-reviewed publications from an extensive query of Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception to March 2022 for all studies that reported the association between alcohol consumption in terms of quantity (daily or weekly amounts) and type of beverage (wine, beer or spirit) and cardiovascular disease events. Results: The study population included a total of 1,579,435 individuals based on 56 cohorts from several countries. We found that moderate wine consumption defined as 1-4 drinks per week was associated with a reduction in risk for cardiovascular mortality when compared with beer or spirits. However, higher risk for cardiovascular disease mortality was typically seen with heavier daily or weekly alcohol consumption across all types of beverages. Conclusions: It is possible that the observational studies may overestimate the benefits of alcohol for cardiovascular disease outcomes. Although moderate wine consumption is probably associated with low cardiovascular disease events, there are many confounding factors, in particular, lifestyle, genetic, and socioeconomic associations with wine drinking, which likely explain much of the association with wine and reduced cardiovascular disease events. Further prospective study of alcohol and all-cause mortality, including cancer, is needed.
KW - Alcohol consumption
KW - Beer consumption
KW - Cardiovascular disease
KW - Liquor consumption
KW - Wine consumption
UR - http://www.scopus.com/inward/record.url?scp=85133406171&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2022.04.021
DO - 10.1016/j.amjmed.2022.04.021
M3 - Article
C2 - 35580715
AN - SCOPUS:85133406171
JO - American Journal of Medicine
JF - American Journal of Medicine
SN - 0002-9343
ER -